India Glycols Ltd - Q1 FY27 Earnings Call Summary
Friday, August 14, 2026, 4:00 PM IST
Event Participants
Executives
6 Anand Singhal (CFO), Rupak Saraswat (CEO), Manoj Kumar Rai (COO - Spirits & Ethanol), S.K. Shukla (Head of Liquor Business), Ankur Jain (Head of Legal & Company Secretary), Akshay Bansal (Executive Director, NH Biopharma)
Analysts
6 Aakash Gupta (Individual Investor), Amit Mishra (Daksham Capital), Pragyan Rakesh Laddha (Omni Management LLP), Ragini Ramkumar (NewGen Capital), Saket Kapoor (Kapoor Company), Vignesh Iyer (Sequent Investments)
Financials & KPIs
| Metric | Reported | Commentary |
|---|---|---|
| Gross Revenue | ₹1,129 crores | Up 19% YoY; driven by growth across all segments |
| Net Revenue | ₹1,130 crores | Up 9% YoY on consolidated basis |
| EBITDA | ₹170 crores | Up 13% YoY; record quarterly EBITDA |
| EBITDA Margin | 15.0% | Improved from 14.3% in Q1 FY26; margin recovery trajectory continues |
| PAT | — | Up 32% YoY |
| Finance Costs | ~₹20 crores | Declined ₹25 crores YoY from ₹45 crores in Q1 FY26; debt reduction supporting profitable growth |
| Debt-to-Equity | Improved | Continued deleveraging during the quarter |
| EBITDA Margin Trend | FY22: 11%, FY23: 13%, FY24: 14.2%, FY25: 14%, FY26: 16.4% | Consistent margin expansion over 4-year strategic plan |
Segment Financials (Q1 FY27):
| Segment | Net Revenue | EBITDA | EBITDA Margin |
|---|---|---|---|
| India Spirits (IGL Spirits) | ₹694 crores | ₹122 crores | 17.3% vs 14.7% Q1 FY26 |
| India Glycols (INDIAGLYCO/Chemicals incl. gases) | ₹345 crores | ₹40 crores | 11.6% (up 12% YoY EBITDA) |
| NH Biopharma | ₹90 crores | ₹10 crores | 11.1% (EBITDA up ~100% YoY) |
Geographic & Segment Commentary
Spirits Business (IMFL + Non-IMFL): Net revenue of ₹371 crores with EBITDA margin of 22.9%, improving 207 bps YoY. IMFL segment grew 26% YoY with 1.4 million cases (55% volume growth), with Prestige-and-above segment at ~0.5 million cases, nearly double last year. Non-IMFL revenue at ₹279 crores with 7.5 million cases (6% volume growth), maintaining dominant position in UP despite declining market where competitors have lost share. The company is the largest ENA manufacturer with exclusive spirit maturation facility for Bacardi, reinforcing manufacturing excellence and cost advantages.
Biofuels Business: Net revenue of ₹323 crores (7% growth) with EBITDA margin of 10.8%, improving 250 bps YoY. EBIT up 19% to ₹27 crores with margin at 8.4%. Growth was aided by reduced ethanol disadvantage versus Reliance pricing, which improved specialty chemical uptake and competitiveness.
Chemicals Business (India Glycols continued entity): Net revenue of ₹332 crores, up 25% YoY with EBITDA margin of 11.4%. Gases business contributed ₹13 crores with 23.1% EBITDA margin. Green solvents/glycols/glycol ethers volumes up 6%, value up 13%, gross margins close to 50%. Glycols value up 83%. Performance chemicals grew 40%, lower than targeted due to Middle East export collapse and raw material supply disruptions. Bio-based amines (world-first) and carbon-smart ethoxylates now in early commercialization. Strategic partnerships with BFF, Dow, L'Oréal, Unilever, NIBEL.
NH Biopharma: Best-ever quarterly performance with revenue of ₹83 crores (over 30% growth QoQ). Thyrotoxicoside sales up 26% QoQ with strong order pipeline and improved price realization. Nicotine sales doubled QoQ driven by European customer conversions; new nicotine food processing operations started at Kandipur plant. Focus on branded nutraceutical portfolio with new certificate approvals for global market penetration.
Company-Specific & Strategic Commentary
Business Restructuring (Demerger): NCLT sanctioned scheme of arrangement on July 17, 2026. Upon effectiveness, the company splits into three entities: (1) India Glycols Ltd - bio-based chemicals, specialty glycols, performance chemicals, gases; (2) Ideal Spirits Ltd - potable spirits (IMFL + country liquor) plus biofuels business leveraging ethanol synergies; (3) NH Biopharma - nutraceuticals, APIs, plus biopolymers from chemical business. Operating synergies retained through shared services arrangements.
Spirits Growth Strategy: New product launches planned in deluxe whiskey, semi-premium vodka segments and white spirits focus. Strategic partnership with Amrut - acquired brands for distribution/marketing in select North Indian states; targeting doubling Amrut whiskey volumes and 10,000+ cases of single malt in operating states. Defence segment to provide all-India footprint with 3-4 new brands (3 approved, 1 pending).
Premiumization & Margin Recovery: Consistent margin expansion from 11% in FY22 to 16.4% in FY26, driven by better feedstock management, cost control, and portfolio quality improvement. IMFL premiumization story continues with Prestige-and-above cases nearly doubling YoY.
Chemicals Innovation Pipeline: Aspirational target of ₹2,500 crores revenue and ₹400 crores EBITDA in 4-5 years. CapEx-light model with incremental ₹5-20 crores this year; modular expansions expected. Gross margins targeted to improve from ~16-17% to ~30% through premium mix and innovative products. New breakthrough technologies under development (low-carbon footprint products) not yet quantifiable.
Investor Relations Enhancement: New IR head Gagan Kwatra (15 years experience, ex-Jubilant Foodworks, KPMG) appointed; revamped investor presentation with segment-wise disclosure.
Guidance & Outlook
| Metric | Guidance / Outlook | Commentary |
|---|---|---|
| Spirits + Biofuels EBITDA (FY27) | In excess of ₹500 crores | ₹120 crores delivered in Q1; driven by IMFL doubling volumes, premium launches, deeper penetration in existing states |
| IMFL Volume Growth (FY27) | Doubling of last year's volumes (3.4 million cases FY26) | Industry growing only 4-5% CAGR; growth from deluxe whiskey, rum, semi-premium vodka launches despite stagnant industry |
| IMFL Revenue Share (FY27) | >30% of potable spirits revenue | Increasing mix shift toward higher-value IMFL |
| Debt-Free Status (Spirits entity) | From FY28 onwards | Based on continued premiumization and growth in operating/new states |
| Ideal Spirits EBITDA (4-5 years) | In excess of ₹1,000 crores | Targeting top 5 alcoholic beverage company in India |
| Chemicals Business (4-5 years) | ~₹2,500 crores revenue; ₹400 crores EBITDA | Aspirational (explicitly not projection); product-by-product, customer-by-customer plan |
| Chemicals Gross Margin (5-6 years) | ~30% | Current ~16-17%; driven by premium mix, innovative product pricing, viable new feedstocks |
| NH Biopharma EBITDA (4-5 years) | ₹130-250 crores | Aspirational; driven by nicotine expansion, branded nutraceuticals, customer expansion |
Risks & Constraints
| Risk | Context |
|---|---|
| Geopolitical Conflict Impact | War created mixed impacts - crude spiked to 4-year high (tailwind for ethylene oxide competitiveness), but rupee hit record low and westbound freight jumped 5-20x, collapsing Middle East oil & gas chemical sales and hampering US shipments |
| Raw Material Availability | Propylene oxide either unavailable or prohibitively expensive, adversely impacting oil & gas sector specialty chemical supply within India and Middle East exports; thyrotoxicoside raw material availability/pricing volatile and expected to remain a challenge in Q2 |
| Industry Stagnation in Traditional Spirits | Industry declining/stagnant in non-IMFL segment where company has dominant position; growth dependent on IMFL premiumization and new state expansions |
| Aspirational vs. Projected Targets | Management emphasized aspirations are not projections; dynamic world conditions could impact delivery timelines and quantum |
Q&A Highlights
FY27 Spirits Guidance
- Question: What is the guidance for potable spirits for this year and next year? (Ragini Ramkumar)
- Answer: EBITDA in excess of ₹500 crores for current year, with ₹120 crores already delivered in Q1. Doubling IMFL volumes from last year based on deeper penetration in operating states with larger brand offerings in deluxe whiskey, rum, and semi-premium vodka segments. Industry growth last 3 years has been 4-5% CAGR; next year expected to continue growing in healthy double digits. (Manoj Kumar Rai)
NH Biopharma/Performance Chemicals CapEx & Aspirations
- Question: What is CapEx planned for the year and how will the performance chemicals business scale up? (Saket Kapoor)
- Answer: Incremental CapEx of ₹5-10-15-20 crores this year; modular expansion model — not a ₹400-500 crore plant. Aspiration of ₹150+ crores this year, growing to ₹600-700 crore business in 4-5 years. Gross margins currently 16-17% targeted to reach ~30% by 2030-2035 through mix improvement and viable new feedstocks. (Rupak Saraswat)
Clarion JV Performance
- Question: JV profit of ₹21 crores this quarter — is this sustainable? Last year annualized was ₹46-47 crores. (Saket Kapoor)
- Answer: Fair assumption; PAT was closer to ₹19 crores in same quarter last year, so ₹21 crores is not unexpected. JV net revenue up 21% QoQ with high double-digit EBITDA growth. Growth driven by reduced ethylene oxide pricing disadvantage, strong performance from Kashipur and Clarion products sold in India, and increased export thrust of India-made products to Clarion customers worldwide. (Rupak Saraswat)
Prestige-and-Above Volume & FY26 Comparison
- Question: What is the prestige-and-above segment volume and growth in IMFL? (Vignesh Iyer)
- Answer: Prestige-and-above is roughly 0.5 million cases, almost double last year's same period. Total IMFL cases for FY26 was 3.4 million. Revenue for IMFL full year not available on call; company to provide offline. (Manoj Kumar Rai)
Amrut Partnership Details
- Question: Is the Amrut partnership structure same for all 5 products (Macintosh Whiskey, Macintosh White, Prestige Green Fusion, Single Malt, Amalgam)? What is the royalty? (Aakash Gupta)
- Answer: Partnership covers distribution/marketing of all 5 products in select North Indian markets, with plans to extend to Eastern markets where Amrut has insignificant presence (they are concentrated in West/South). Royalty terms not disclosed as commercially sensitive. (Manoj Kumar Rai, Anand Singhal)
QoQ EBITDA Decrease Explanation
- Question: EBITDA declined from ₹203 crores in Q4 FY26 to ₹170 crores in Q1 FY27 — why the negative growth? (Aman, individual investor)
- Answer: Last quarter (Q4 FY26) included dividend income from Clarion of approximately ₹39 crores. Dividend income comes in the fourth quarter each year; no such income in the current quarter. (Anand Singhal)
Volume Growing Faster Than Revenue
- Question: Cases grew this year but revenue didn't grow proportionately despite premiumization claims — what's the reason? (Pragyan Rakesh Laddha)
- Answer: Two reasons: state mix and brand mix. Higher growth from Uttarakhand is favorable, higher growth from Delhi less favorable. In brand mix, mass premium segment grew faster due to new offerings in those segments. Going forward, launches in deluxe whiskey, semi-premium vodka, and white spirits (which have high margins) will result in revenue growth exceeding volume growth as premium mix improves. (Manoj Kumar Rai)
IMFL vs Country Liquor Revenue Split and Margins
- Question: What percentage of FY27 revenue will come from IMFL? What are the EBITDA margins for IMFL and country liquor? (Amit Mishra)
- Answer: IMFL revenue will be in excess of 30% of potable spirits revenue. Semi-premium whiskey offerings have nearly same gross margins as country liquor, contrary to common investor perception. (Manoj Kumar Rai)
Key Takeaway
India Glycols Ltd delivered a strong Q1 FY27 with consolidated net revenue of ₹1,130 crores (up 9% YoY), record EBITDA of ₹170 crores (up 13%), and PAT up 32%. The quarter was characterized by margin recovery across all segments — spirits EBITDA margin improved 207 bps to 22.9%, biofuels improved 250 bps to 10.8%, and overall EBITDA margin reached 15% (up from 14.3% YoY). IMFL volumes grew 55% with 1.4 million cases, of which 0.5 million were prestige-and-above (nearly doubled YoY), supported by the strategic Amrut partnership targeting 10,000+ single malt cases. The NCLT-approved demerger into three entities (India Glycols, Ideal Spirits, NH Biopharma) is progressing, designed to unlock value through focused business structures and investor clarity. Management provided FY27 EBITDA guidance of ₹500+ crores for the combined spirits/biofuels business, while framing chemicals (₹400 crores EBITDA) and biopharma (₹130-250 crores) targets as aspirations rather than projections. Finance costs dropped ₹25 crores YoY on continued deleveraging, positioning the spirits entity for debt-free status by FY28. War-related impacts created both tailwinds (improved ethylene oxide competitiveness vs. Reliance) and headwinds (Middle East export collapse, freight volatility), while thyrotoxicoside raw material challenges persist. With 4-5 year aspirations of becoming a top-5 Indian alcoholic beverage company and building a ₹2,500 crore chemicals business, management's strategic execution and margin trajectory remain the key watch points for investors.